Could a simple immunization shield cancer patients from severe COVID-19?
NCT ID NCT04442048
First seen Jan 04, 2026 · Last updated Jun 22, 2026 · Updated 28 times
Summary
This phase 3 trial tested whether a biologic called IMM-101 could reduce severe respiratory infections, including COVID-19, in cancer patients at higher risk. 195 participants either received three doses of IMM-101 or were simply observed. The goal was to see if the treatment could prevent flu-like illness that disrupts cancer care or leads to hospitalization.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHUM-Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2X 3E4, Canada
-
CIUSSS de l'Estrie - Centre hospitalier
Sherbrooke, Quebec, J1H 5N4, Canada
-
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, L8V 5C2, Canada
-
London Regional Cancer Program
London, Ontario, N6A 5W9, Canada
-
Odette Cancer Centre
Toronto, Ontario, M4N 3M5, Canada
-
Ottawa Hospital Research Institute
Ottawa, Ontario, K1H 8L6, Canada
-
The Research Institute of the McGill University
Montreal, Quebec, H4A 3J1, Canada
-
University Health Network
Toronto, Ontario, M5G 2M9, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IMM-101 (a biologic vaccine-like agent)
What this could lead to
If it works, this could provide a way to help protect cancer patients from severe respiratory infections, including COVID-19.
What could go wrong
This trial is completed but results are not yet widely reported, so it is unclear if IMM-101 was effective. The study was also relatively small (195 participants), so findings may not apply to all cancer patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.